
After the July 12 day-long meeting, the FDA panel unanimously recommended that the agency approve the treatment. But what does this mean for patients? And is CAR T-cell therapy going to play an increasing role in cancer treatment in general? In this interview, Leonard Lichtenfeld, MD, MACP, American Cancer Society deputy chief medical officer, gives us his take.
Read more Click Here